| Acquired by | GlaxoSmithKline |
| Price | $57M |
| Date | 11/08 |
| Terms | Cash |
| Website | genelabs.com |
| Category | BioTech |
| Phone | 650-369-9500 |
| Employees | 76 |
| Founded | 1983 |
| TOTAL | $17.3M |
| FUNDING TOTAL | $17.3M |
| Venture Round, 6/06 RA Capital Management Fort Mason Capital Centrecourt Asset Management Merlin Biomed Paramount BioCapital Asset Management | $8.3M |
| Venture Round, 6/07 | $9M |
As of January 6, 2009, Genelabs Technologies Inc. was acquired by SmithKline Beecham Corporation. Genelabs Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of infectious disease therapies to improve human health. The company’s product pipeline consists of infectious disease projects focusing on Hepatitis C virus infection; and late-stage clinical assets, including an investigational vaccine for hepatitis E virus that is being developed by GlaxoSmithKline; and Prestara, an investigational drug for systemic lupus erythematosus. It has license and collaboration agreement with the Novartis Institutes for BioMedical Research for HCV polymerase non-nucleoside discovery research. Genelabs Technologies also has a collaborative research agreement with the National Health Research Institutes and Genovate Biotechnology Co., Ltd. to discover and develop compounds that target the hepatitis C virus. The company was founded in 1983 and is headquartered in Redwood City, California.
